{
    "nct_id": "NCT06220604",
    "official_title": "A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis",
    "inclusion_criteria": "* Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention\n* Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline\n* Total psoriasis area and severity index (PASI) >=12 at screening and baseline\n* Total investigator global assessment (IGA) >=3 at screening and baseline\n* Candidate for phototherapy or systemic treatment for plaque psoriasis\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)\n* Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)\n* A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances\n* Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib or to any of the excipients or components of the study intervention\n* Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study",
    "miscellaneous_criteria": ""
}